14 results
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
relies, and expects to continue to relying, on third parties to package, label, store and distribute their investigational product candidates
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
or necessary to make the statements therein not misleading. As of the Time of Sale (as defined below), neither (A) the Time of Sale Disclosure Package … (as defined below) nor (B) any issuer free writing prospectus (as defined below), when considered together with the Time of Sale Disclosure Package
DEF 14A
eig6cqfptq 4k901
28 Apr 22
Definitive proxy
8:36am
424B3
4px25xkr4 g5cu5qetxo
5 Aug 21
Prospectus supplement
4:26pm
S-4/A
EX-10.19
8z6t0q1
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.12
edt0 6fwui
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.12
xeyni6
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K
EX-1.1
6599kdj4szotolh
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm
S-1
EX-1.1
mkf5bk
15 Jun 20
IPO registration
5:28pm
- Prev
- 1
- Next